title: Adverse events of unapproved drugs in Japan.
authors.forename: Shigesaburo
authors.initials: S
authors.lastname: Miyakoshi
authors.forename: Eiji
authors.initials: E
authors.lastname: Kusumi
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kodama
authors.forename: Hiroto
authors.initials: H
authors.lastname: Narimatsu
authors.forename: Tamae
authors.initials: T
authors.lastname: Hamaki
authors.forename: Tomoko
authors.initials: T
authors.lastname: Matsumura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kami
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003257:Consumer Product Safety; D017277:Drug Approval; D004348:Drug Labeling; D033161:Government Regulation; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007564:Japan; D008389:Marketing of Health Services; D010353:Patient Education as Topic; D028701:Patient Rights; D018579:Patient Selection; D011719:Pyrazines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib